By David Bautz, PhD
OTC:ATBPF | TSX:ATE.TO
READ THE FULL ATE.TO RESEARCH REPORT
Business Update
Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22
Antibe Therapeutics, Inc. (OTC:ATBPF) (TSX:ATE) is developing otenaproxesul as a solution to the dose-related gastrointestinal (GI) side effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). It uses naproxen as a base molecule with a hydrogen sulfide moiety covalently attached. Hydrogen sulfide (H2S) is an important gasotransmitter, which is a gas that serves as an important signaling molecule in the body.
The company is developing otenaproxesul for the management...
Login or create a forever free account to read this news
Sign up/Log in